FGFR2 Antibody

Code CSB-PA000992
Size US$167
Image
  • Western Blot analysis of A549 cells using Bek Polyclonal Antibody
  • Western Blot analysis of HuvEc cells using Bek Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P21802
Target Names FGFR2
Alternative Names bacteria-expressed kinase antibody; BBDS antibody; BEK antibody; BEK fibroblast growth factor receptor antibody; BFR1 antibody; CD332 antibody; CD332 antigen antibody; CEK3 antibody; CFD1 antibody; Craniofacial dysostosis 1 antibody; ECT1 antibody; FGF receptor antibody; FGFR 2 antibody; FGFR-2 antibody; Fgfr2 antibody; FGFR2_HUMAN antibody; Fibroblast growth factor receptor 2 antibody; Hydroxyaryl protein kinase antibody; Jackson Weiss syndrome antibody; JWS antibody; K SAM antibody; K-sam antibody; Keratinocyte growth factor receptor 2 antibody; Keratinocyte growth factor receptor antibody; KGFR antibody; KSAM antibody; protein tyrosine kinase; receptor like 14 antibody; soluble FGFR4 variant 4 antibody; TK14 antibody; TK25 antibody
Raised in Rabbit
Species Reactivity Human,Mouse,Rat
Immunogen Synthesized peptide derived from the Internal region of Human Bek.
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Isotype IgG
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form Liquid
Tested Applications WB, IHC, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:10000
Protocols Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Citations

miR124-3p/FGFR2 axis inhibits human keratinocyte proliferation and migration and improve the inflammatory microenvironment in psoriasis. Y Xiao,Mol Immunol,2020

Applications: Immunoblotting
Review: The protein levels of FGFR2 in psoriasis lesion and non-lesion tissues were determined by immunoblotting.
PMID: 20200426

Target Data

Function Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.
Gene References into Functions
  1. The results showed no association between two SNPs, rs1219648 and rs2981582, and breast cancer risk, although in a stratified analysis rs2981582 strongly associated with premenopausal and ER-positive breast cancer in Chinese patients. PMID: 30480917
  2. The consequent appearance of the mesenchymal FGFR2c variant in the epithelial context would drive early steps of carcinogenesis. PMID: 29068468
  3. FGFR2 was shown to be markedly overexpressed in gastric cancer tissues and correlated with a high risk of lymph node metastasis and late clinical stage. FGFR2 was negatively associated with TSP4 and FGFR2 activation could downregulate TSP4 expression, which played an important role in the proliferation, invasion and migration of gastric cancer cells. PMID: 30355943
  4. In male breast cancer, smoking habits had a significant effect on overall survival at 10 years. In the same multivariate analysis, we found a significantly higher overall survival in cases with FGFR2 rs2981582 variant in the dominant transmission model A sensitivity analysis with left truncation showed similar results. PMID: 29709729
  5. Results showed that HER2 and FGFR2 are regulated by DDX6 at the post-transcriptional step in gastric cancer. PMID: 29987267
  6. High FGFR2 expression is associated with epithelial ovarian cancer cell proliferation and invasion. PMID: 29970688
  7. There is a wide spectrum of mutations in FGFR2 shown to be causative for Pfeiffer syndrome. Here we report the first Chinese three-generation family with FGFR2 mutation c.514_515delGCinsTT (p.Ala172Phe). PMID: 29782338
  8. It was concluded that miR494 inhibited the cancer initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2positive gastric cancer. PMID: 29786108
  9. Patients with very strong FGFR2 mRNA expression showed more homogeneous FGFR2 mRNA expression compared to patients with lower FGFGR2 mRNA expression PMID: 28852882
  10. provide a comprehensive update on FGFR2-related syndromic craniosynostosis PMID: 29230096
  11. The mutations were not present in any of the unaffected family members or unrelated control subjects. These findings expand the mutation spectrum of FGFR2, and are valuable for genetic counseling in addition to prenatal diagnosis in patients with Crouzon syndrome. PMID: 28901406
  12. Fibroblast growth factor receptor 2 (FGFR2) splice site variants were identified in eight patients with Crouzon or Pfeiffer syndrome. PMID: 26841243
  13. Data suggest that the SOX9 transcription factor (SOX9)-fibroblast growth factor receptor 2 (FGFR2b) feed-forward loop has a lineage dependency role in pancreatic ductal adenocarcinoma (PDAC). PMID: 28796141
  14. this study reports for the first time the p.W290G mutation in patients with PS. Based on clinical features, genetic, and computational analysis and genotype-phenotype association studies PMID: 28815901
  15. Studies indicate that switching from fibroblast growth factor receptor 2 (FDFR-2) IIIb to IIIc variants correlates with the aggressiveness of the cancers via epithelial-mesenchymal transition [Review]. PMID: 28930565
  16. These results unveil the complexity of ER regulation by FGFR2-mediated signaling likely to be associated with BCa resistance to endocrine therapy. PMID: 28869838
  17. Study report that 5-10% of epidermal nevi harbor embryonic postzygotic FGFR2 activating mutations. PMID: 27103312
  18. this study identified an FGFR2 in two Chinese patients with syndromic craniosynostosis. The finding expands the reported mutation spectrum of FGFR2, and is of great value for genetic counseling and prenatal diagnosis in families with syndromic craniosynostosis. PMID: 28849010
  19. Through a stratification analysis, 5q11.2/MAP3K1 (rs16886034, rs16886364, rs16886397, rs1017226, rs16886448) and 7q32.3/LINC-PINT (rs4593472) were associated with Luminal A, and 10q26.1/FGFR2 (rs35054928) was associated with Luminal B. PMID: 28408616
  20. SNORD126 activates the PI3K-AKT pathway by upregulation of FGFR2. PMID: 27913571
  21. This study reveals a direct binding event and characterizes the role of TRPA1 ankyrin repeats in regulating FGFR2-driven oncogenic process; a mechanism that is hindered by miRNA-142-3p PMID: 29038531
  22. Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy. PMID: 27802183
  23. This meta-analysis of case-control studies provides strong evidence that FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms were significantly associated with the BC risk. PMID: 27966449
  24. we further refine the influence of variants in the FGFR2 locus with respect to molecular characteristics of breast tumors, in that they are more strongly associated with estrogen receptor status among cancers without amplification of the HER2 gene. PMID: 27764800
  25. Suggest FGFR2 as a novel acute myeloid leukemia susceptibility gene with a haplotype TT (rs7090018 and rs2912759) showing significant association with AML. PMID: 27903959
  26. Result demonstrated that FGFR2 high-expression was significantly associated with unfavorable prognosis of gastric adenocarcinoma and that SPRY2 could inhibit FGFR2-induced ERK phosphorylation and suppress FGFR2-elicited gastric cancer cell proliferation and invasion. PMID: 28002800
  27. By means of structural (X-ray and NMR) and functional characterization of pathogenic gain-of-function mutations affecting the FGF receptor (FGFR) tyrosine kinase domain, the authors elucidated a long-distance allosteric network composed of four interconnected sites termed the 'molecular brake', 'DFG latch', 'A-loop plug', and 'alphaC tether'. The first three sites repress the kinase from adopting an active conformation... PMID: 28166054
  28. Besides, we found miR-628-5p targeted at and down-regulated the expression of fibroblast growth factor receptor 2 (FGFR2). FGFR2 expressed higher in ovarian cancer tissues and was correlated with worse prognosis. Our findings indicated that miR-628-5pplays an important role in ovarian cancer stem cell driven tumorigenesis. PMID: 29229394
  29. Mandibular growth in children with FGFR2 mutations is not normal with impairments found in forward sagittal growth and skull base widening PMID: 28468153
  30. Inhibiting Fgf-R partly reversed alphavbeta3 integrin activity in Mll-Ell+ progenitor cells. PMID: 27340869
  31. In gastric cancer, FGFR2 protein overexpression predicts gene amplification and poor survival. PMID: 27230412
  32. Her2, cMet and FGFR2 statuses were profiled in gastric cancer (GC) patients and the -derived tumor xenograft(PDX) models. PMID: 28292264
  33. We demonstrate that the bent bone dysplasia syndrome mutations in FGFR2 p.M391R and p.Y381D augment the ability of FGFR2 to epigenetically activate rDNA. Mutations p.M391R and p.Y381D activate the p53 nucleolar stress response pathway and alter FGFR2-mediated activation of ribosome biogenesis. PMID: 28595297
  34. Polyclonal secondary FGFR2 mutations represent an important clinical resistance mechanism to protein kinase inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma. PMID: 28034880
  35. CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription. PMID: 27107424
  36. a novel identical postzygotic activating FGFR2 mutation in two unrelated fetuses with papillomatous pedunculated sebaceous naevus. PMID: 27095246
  37. Findings suggest fibroblast growth factor receptor 2 (FGFR2) as a therapeutic target for esophagogastric junction (EGJ) adenocarcinoma. PMID: 26933914
  38. Description of these patients expands the prenatal and postnatal findings of Bent Bone Dysplasia-FGFR2 type and adds to the phenotypic spectrum among all FGFR2 disorders. PMID: 27240702
  39. Our results imply that the same FGFR2 mutations result in diverse phenotypes, and that genetic studies are recommended not only for obviously affected individuals but also for family members with apparently normal phenotype or non-specific subtle abnormal phenotype. PMID: 27683237
  40. Liensinine inhibits FGFR2 activity. PMID: 28132898
  41. FGFR2-ACSL5 fusion is associated with resistance to LY2874455 in FGFR2-amplified gastric cancer . PMID: 28122360
  42. FGFR2 mutation is associated with endometrial carcinoma progression and abdominopelvic metastasis. PMID: 27348297
  43. FGFR inhibitors, particularly BGJ398, are therapeutic options for cholangiocarcinoma patients harboring FGFR2-CCDC6 fusions. PMID: 27216979
  44. High FGFR2 expression is associated with Gastric Cancers. PMID: 27197184
  45. Two novel FGFR 2 gene missense mutations in Chinese patients with Crouzon syndrome were identified. PMID: 27430617
  46. Incidence of progression (progressed, recurred or died from disease) of endometrioid endometrial cancer was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p<0.001, Chi-square test). PMID: 28314589
  47. We show that this stabilizes the tyrosine and primes it for the catalytic phosphotransfer, and it may lower the activation barrier of the phosphotransfer reaction. Our work demonstrates the value of including dynamic information gleaned from computer simulation in deciphering RTK regulatory function. PMID: 28151998
  48. We show that the decrease in PI(4,5)P2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plc11 and Grb2 correlate with patient survival PMID: 26212011
  49. High FGFR2 expression was significantly associated with the depth of invasion, lymph-node metastasis, pathological stage, and distant metastasis or recurrent disease in gastric cancer. PMID: 28056982
  50. fibroblast growth factor receptor 2 overexpression is correlated with decreased survival in most solid tumors, suggesting that the expression status of fibroblast growth factor receptor 2 is a valuable prognostic biomarker and a novel therapeutic target in human solid tumors. PMID: 28618942
  51. We thus propose a molecular mechanism by which FGFR2 can confer increased breast cancer risk that is consistent with oestrogen exposure as a major driver of breast cancer risk. Our findings may have implications for the clinical use of FGFR2 inhibitors. PMID: 27236187
  52. There was an increased effect of Breast Cancer risk between haplotype combinations of the two Single nucleotide polymorphisms of FGFR2 (rs2981582 and rs1219648) in Pakistani women. PMID: 27572905
  53. Our meta-analysis suggests that FGFR2 is likely an important genetic marker contributing to susceptibility of BC. We recommend that these single nucleotide polymorphisms to be included in future association studies and functional assays. PMID: 27461607
  54. FGFR2 expression by IHC might be a useful biomarker for predicting treatment outcomes of patients with metastatic or recurrent AGC treated with a combination of pazopanib and CapeOx PMID: 26983912
  55. Although FGFR2 over-expression did not independently influence patient outcome, FGFR2 over-expression was associated with worse prognosis and inferior tumor regression grading in residual disease after preoperative chemoradiotherapy \ in patients with rectal cancer PMID: 26831663
  56. Upregulated expression of FGFR2 is associated with breast cancer. PMID: 27476168
  57. FGFR2 overexpression is associated with metastatic papillary renal cell carcinoma. PMID: 27379982
  58. This article reports what we believe to be the 25th case of BSS, exhibiting a constellation of the characteristic features, but is one of the very few cases lacking craniosynostosis at birth, as well as having a natal tooth encompassed by a cyst. PMID: 27079505
  59. Our results indicate that FGFR2 and PAPSS2 may play an important role in the regulation of magnesium homeostasis in children of European-American ancestry. PMID: 26685716
  60. for the first time, report the molecular mechanisms by which AP24534 exerts antitumor effects on ECs with FGFR2 activating mutations, which would provide mechanistic insight into ongoing clinical investigations of AP24534 for ECs. PMID: 26574622
  61. Results suggest, a potential role for PIK3CA, VEGFR2, RET and FGFR2 as therapeutic targets in EGFR non-mutated NSCLC that requires further clinical validation. PMID: 26853422
  62. Formononetin targets the FGFR2-mediated Akt signaling pathway, leading to the suppression of tumor growth and angiogenesis in breast neoplasms. PMID: 26575424
  63. The association of the FGFR2 gene with risk of overall and ER-positive breast cancer. PMID: 26743380
  64. FGFR2 is a breast cancer susceptibility gene. PMID: 26728143
  65. this study shows preliminary evidence for the role of FGFR signaling in the proliferation and differentiation of Apert dental pulp and enamel organ epithelia cells. PMID: 26613250
  66. High FGFR2 expression is associated with colorectal cancer. PMID: 26506517
  67. intratumoral heterogeneity and discordant FGFR2b expression in primary tumors and metastatic lymph nodes are common in gastric cancer PMID: 26516773
  68. Missense mutations in the FGFR2 gene provide a therapeutic target for AZD4547 in FGFR2-deregulated endometrial cancer cells. PMID: 26294741
  69. associations of FGFR2 single nucleotide polymorphisms with breast cancer were heterogeneous according to intrinsic subtype. PMID: 26421298
  70. Study demonstrates overexpression of FGFR2 and a functional role of FGFR signaling in myxoid liposarcoma. PMID: 26036639
  71. that STAT-5, RUNX-2, and FGFR-2 may have a role in the progression of the mucinous phenotype, in which nuclear STAT-5 may inhibit RUNX-2 prometastatic effect PMID: 26551078
  72. Data suggest that a subset of non-small cell lung cancer cells express VEGFR2 promoting VEGF-dependent tumor growth. Targeting VEGFR2 signaling, such as cediranib, will have the potential to inhibit both tumor cell proliferation and angiogenesis. PMID: 26179332
  73. results indicated the prevalence of FGFR2 mutational status in the Taiwanese population with endometrial cancer. PMID: 25517871
  74. FGFR2 amplification tended to result in a shorter survival period compared to cases without amplification. PMID: 26254407
  75. The clinical features were consistent with the diagnosis of Apert syndrome, which was confirmed by the presence of the P253R point mutation in FGFR2. PMID: 25714562
  76. The results from this study suggest that the FGFR2 C-906T polymorphism may be associated to breast cancer in population studied. PMID: 26025410
  77. analysis of FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma PMID: 25608663
  78. Diffuse-type gastric cancer cells might switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis through HIF1 in hypoxic tumor microenvironments. PMID: 26385890
  79. The importance of the FGFR2-Mre11-DSBR link in cancer progression is suggested by the finding that genotypes of FGFR2 and Mre11 are associated with survival of breast cancer patients PMID: 25788520
  80. TOX3 and FGFR2 are breast cancer susceptibility genes in BRCA1/2-wild-type breast cancer patients from Sardinian population. PMID: 25956309
  81. High expression of FGFR2 is associated with clear cell carcinoma of the ovary. PMID: 25756405
  82. A transcriptional crosstalk among 16E5 and KGFR might be the crucial molecular driver of epithelial deregulation during early steps of HPV infection and transformation. PMID: 25826082
  83. Data indicate the mutations in exon IIIa of fibroblast growth factor receptor 2 (FGFR2) in Mexican Apert syndrome (AS) patients. PMID: 25867380
  84. Results indicate that VEGFR2 -906, COX-2 -1195 and MMP-2 -1306 variants and their combinations may signi fi cantly in fl uence clinical outcome in inoperable non-small cell lung cancer patients treated with radiotherapy with or without chemotherapy. PMID: 25975224
  85. Data suggest combination targeted therapeutic strategy for treating fibroblast growth factor receptor 2 (FGFR2) amplified gastric cancer (GC) patients with multiple receptor tyrosine kinase activations. PMID: 25576915
  86. The findings suggest that the C342R mutation in FGFR2 may cause Crouzon syndrome and elbow deformity in Chinese patients. PMID: 25759925
  87. Here, we report on a child with a clinically diagnosed Crouzon syndrome that shows the missense point mutation S267P in FGFR2 gene. PMID: 25759927
  88. The findings suggest that abnormal calcification was atypical phenotype of Crouzon patients with Cys342Tyr mutation in FGFR2. PMID: 25692891
  89. Report shows that FGFR-2 is expressed at lower levels in high histological grade gliomas, and that decreased FGFR-2 expression may be related to lower survival rates. PMID: 24968791
  90. novel FGFR2 extracellular domain insertion mutations PMID: 26048680
  91. FGFR2 is amplified and highly expressed in NCI-H716 cells. PMID: 24968263
  92. FGFR2 tyrosine kinase fusions are associated with aggressive molecular subtype of non-small cell lung cancer. PMID: 24850843
  93. Twist1 and FGFR2 are highly associated with differentiation of gastric adenocarcinoma; Twist1 can facilitate invasion and EMT in gastric adenocarcinoma via promotion of FGFR2 expression. PMID: 25561797
  94. exercise activity and FGFR2 rs2981582 were confirmed to be associated with breast cancer risk, and were found to significantly interact; there was also a significant interaction between FGFR2 rs2981582 and MTHFR rs1801133 on breast cancer risk PMID: 25270516
  95. Second-line dovitinib in FGFR2(mut) and FGFR2(non-mut) advanced or metastatic endometrial cancer had single-agent activity, although it did not reach the prespecified study criteria. Observed treatment effects seemed independent of FGFR2 mutation status PMID: 25981814
  96. the identification of a novel point mutation in fibroblast growth factor receptor 2 (FGFR2), c.812G>T, p.(Gly271Val) or c.1851G>C, p.(Leu617Phe), is reported. PMID: 25425289
  97. Methylation of the FGFR2 gene is associated with high birth weight centile in humans. PMID: 25431941
  98. Results show that HPV16 E5 down-modulates FGFR2b and induces FGFR2c expression in human keratinocytes and cervical epithelial cells through down-modulation of ESRPs. PMID: 25450802
  99. Activating FGFR2-RAS-BRAF mutations play a critical role in the pathogenesis of most cases of ameloblastoma. PMID: 24993163
  100. Deep-sequencing of a primary tumor and metastasis from a single patient, and functional validation in culture, reveals that FGFR2 and TGFBR2 act as drivers of gastric cancer in primary and metastasis respectively. PMID: 25222187

Show More

Hide All

Involvement in disease Crouzon syndrome (CS); Jackson-Weiss syndrome (JWS); Apert syndrome (APRS); Pfeiffer syndrome (PS); Beare-Stevenson cutis gyrata syndrome (BSTVS); Familial scaphocephaly syndrome (FSPC); Lacrimo-auriculo-dento-digital syndrome (LADDS); Antley-Bixler syndrome, without genital anomalies or disordered steroidogenesis (ABS2); Bent bone dysplasia syndrome (BBDS); Saethre-Chotzen syndrome (SCS)
Subcellular Location Cell membrane, Single-pass type I membrane protein, Golgi apparatus, Cytoplasmic vesicle, Note=Detected on osteoblast plasma membrane lipid rafts, After ligand binding, the activated receptor is rapidly internalized and degraded, SUBCELLULAR LOCATION: Isoform 1: Cell membrane, Single-pass type I membrane protein, Note=After ligand binding, the activated receptor is rapidly internalized and degraded, SUBCELLULAR LOCATION: Isoform 3: Cell membrane, Single-pass type I membrane protein
Protein Families Protein kinase superfamily, Tyr protein kinase family, Fibroblast growth factor receptor subfamily
Database Links

HGNC: 3689

OMIM: 101200

KEGG: hsa:2263

STRING: 9606.ENSP00000410294

UniGene: Hs.533683

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1